The MedAnnex management team has an impressive track record within the biopharmaceutical industry, including the formation and growth of Bioenvision Inc. into a NASDAQ National listed, global biopharmaceutical company, which was acquired in October 2007 by Genzyme Corporation.

MedAnnex has recently secured an investment, led by Alida Capital International, which will take annexuzlimab through to clinical development.

Latest News

November 2017

MedAnnex partners with University College London (UCLC) to further explore annexuzlimab’s potential as a new therapeutic for SLE

November 2017

MedAnnex confirms a 4-year Medical Research Scotland PhD studentship (Glasgow University), exploring the role of annexin and mechanism of action of annexuzlimab in chronic inflammatory disease